Corcept Therapeutics (NASDAQ:CORT) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Thursday.

Other equities analysts have also recently issued reports about the stock. Piper Jaffray Companies set a $30.00 price objective on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $21.00.

Shares of Corcept Therapeutics (NASDAQ CORT) traded down $0.20 during mid-day trading on Thursday, reaching $20.65. 1,318,403 shares of the company’s stock were exchanged, compared to its average volume of 2,468,249. Corcept Therapeutics has a 1 year low of $6.70 and a 1 year high of $21.00. The company has a market capitalization of $2,356.66, a PE ratio of 71.21 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The business had revenue of $42.70 million during the quarter, compared to the consensus estimate of $41.64 million. During the same period in the previous year, the business posted $0.02 earnings per share. Corcept Therapeutics’s revenue was up 96.8% compared to the same quarter last year. research analysts anticipate that Corcept Therapeutics will post 0.47 earnings per share for the current fiscal year.

In other news, insider Robert S. Fishman sold 8,000 shares of Corcept Therapeutics stock in a transaction on Monday, January 8th. The shares were sold at an average price of $18.67, for a total transaction of $149,360.00. Following the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at $149,360. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director G Leonard Baker, Jr. sold 30,000 shares of Corcept Therapeutics stock in a transaction on Monday, November 13th. The stock was sold at an average price of $17.59, for a total transaction of $527,700.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,000 shares of company stock worth $810,820. Insiders own 19.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Corcept Therapeutics by 18.4% during the second quarter. Vanguard Group Inc. now owns 4,440,064 shares of the biotechnology company’s stock worth $52,394,000 after purchasing an additional 689,554 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Corcept Therapeutics by 44.4% during the second quarter. Renaissance Technologies LLC now owns 2,683,400 shares of the biotechnology company’s stock worth $31,664,000 after purchasing an additional 824,900 shares in the last quarter. State Street Corp boosted its position in shares of Corcept Therapeutics by 26.1% during the second quarter. State Street Corp now owns 2,028,013 shares of the biotechnology company’s stock worth $23,931,000 after purchasing an additional 420,139 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Corcept Therapeutics by 41.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,204,325 shares of the biotechnology company’s stock worth $23,242,000 after purchasing an additional 355,006 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Corcept Therapeutics by 74.1% during the third quarter. Prudential Financial Inc. now owns 1,102,483 shares of the biotechnology company’s stock worth $21,278,000 after purchasing an additional 469,260 shares in the last quarter. 64.64% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Corcept Therapeutics (CORT) Upgraded to “Buy” by BidaskClub” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/14/corcept-therapeutics-cort-upgraded-to-buy-by-bidaskclub.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.